Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Papillary | 3 | 2019 | 77 | 0.720 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 2479 | 0.590 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 30 | 0.550 |
Why?
|
| Radiology Department, Hospital | 1 | 2017 | 24 | 0.550 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2019 | 83 | 0.540 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 59 | 0.540 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 229 | 0.470 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 791 | 0.470 |
Why?
|
| Mucin-4 | 1 | 2012 | 11 | 0.410 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 502 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 714 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1232 | 0.250 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 27 | 0.190 |
Why?
|
| Mouth | 1 | 2021 | 59 | 0.180 |
Why?
|
| Veterans Health | 1 | 2021 | 174 | 0.170 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 154 | 0.160 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 271 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 237 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 481 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 151 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1213 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2019 | 1473 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5040 | 0.130 |
Why?
|
| Cell-Matrix Junctions | 1 | 2015 | 8 | 0.120 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 36 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2015 | 60 | 0.120 |
Why?
|
| Glucose | 1 | 2019 | 875 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 63 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 232 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 216 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2017 | 378 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 676 | 0.110 |
Why?
|
| Middle Aged | 7 | 2021 | 26015 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 260 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1593 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 993 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 268 | 0.100 |
Why?
|
| SEER Program | 1 | 2013 | 194 | 0.100 |
Why?
|
| Trastuzumab | 1 | 2012 | 131 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 103 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 400 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3547 | 0.100 |
Why?
|
| Female | 10 | 2022 | 65562 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 3291 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2012 | 230 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 424 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 176 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 4512 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2012 | 694 | 0.090 |
Why?
|
| Gene Expression | 2 | 2012 | 1565 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2012 | 363 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1017 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 352 | 0.080 |
Why?
|
| Veterans | 1 | 2021 | 1734 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 861 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 886 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1012 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2022 | 16062 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1268 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 489 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 2000 | 0.070 |
Why?
|
| Humans | 11 | 2022 | 123180 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 604 | 0.070 |
Why?
|
| Nasal Septum | 1 | 2006 | 17 | 0.070 |
Why?
|
| Cartilage, Articular | 1 | 2006 | 57 | 0.070 |
Why?
|
| Transcriptome | 1 | 2012 | 903 | 0.070 |
Why?
|
| Incidence | 1 | 2013 | 3045 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1439 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12142 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1006 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3565 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1305 | 0.050 |
Why?
|
| Phenotype | 1 | 2012 | 4226 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 44 | 0.050 |
Why?
|
| Glossectomy | 1 | 2021 | 7 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 859 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2021 | 25 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 142 | 0.050 |
Why?
|
| Free Tissue Flaps | 1 | 2021 | 51 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 17542 | 0.040 |
Why?
|
| Collagen | 2 | 2015 | 316 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2012 | 4494 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 822 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 743 | 0.040 |
Why?
|
| Animals | 3 | 2019 | 33798 | 0.040 |
Why?
|
| Aged | 4 | 2021 | 19108 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1237 | 0.040 |
Why?
|
| Male | 3 | 2021 | 60173 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6375 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1599 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 92 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 113 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1172 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1258 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 570 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 496 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 1068 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1394 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 470 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 528 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 533 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 6221 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 576 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 29032 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4288 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1415 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1800 | 0.020 |
Why?
|
| Endopeptidase K | 1 | 2006 | 4 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 12 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2006 | 33 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 73 | 0.020 |
Why?
|
| Anisotropy | 1 | 2006 | 122 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 155 | 0.020 |
Why?
|
| Temperature | 1 | 2006 | 304 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8864 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 176 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 19111 | 0.000 |
Why?
|